Haemonetics (HAE) Misses Q2 EPS by 1c, Lowers FY EPS Guidance

Haemonetics (NYSE: HAE) reported Q2 EPS of $0.60, $0.01 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $239.9 million versus the consensus estimate of $239.99 million.

GUIDANCE:

Haemonetics sees FY2022 EPS of $2.40-$2.65, versus the consensus of $2.76.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c